Less Ads, More Data, More Tools Register for FREE

Pin to quick pickshVIVO Regulatory News (HVO)

Share Price Information for hVIVO (HVO)

Share Price is delayed by 15 minutes
Get Live Data
8.80    0.40 (4.76%)
Bid:
8.60
Ask:
9.00
Spread: 0.40 (4.651%)
Market Cap: £60.58m
HVO Live PriceLast checked at - London Stock Exchange

Intraday hVIVO Share Chart

Contract Win

10 May 2012 14:00

RNS Number : 0894D
Retroscreen Virology Group PLC
10 May 2012
 



 

Retroscreen Virology Group plc ("Retroscreen" or the "Company")

 

Contract Win

 

The Board of Directors of Retroscreen, the AIM-quoted viral challenge quarantine and "Virometrics" specialist, is pleased to announce the signing of a Viral Challenge Model ("VCM") contract with a major US-based biotechnology company for the provision of an influenza challenge study. The contract, which is valued at £3.9m and had previously been under a Start Up Agreement, represents a significant milestone in the Company's growth.

 

Kym Denny, Chief Executive Officer, commented, "We are delighted to be working with such an innovative client on the development of their novel product. This contract is testament to the pharmaceutical industry's increasing awareness of the benefits of the VCM in accelerating drug development and product decision-making."

 

 

Enquiries:

 

Retroscreen Virology Group plc +44 207 756 1300

 

Kym Denny (CEO)

Graham Yeatman (FD)

 

Numis Securities Limited +44 207 260 1000

 

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTBKKDKBBKDAPD
Date   Source Headline
3rd Feb 20257:00 amRNSRSV contract signed with Inhalon Biopharma
31st Jan 20251:24 pmRNSHolding(s) in Company
31st Jan 20257:00 amRNSHolding(s) in Company
29th Jan 20257:01 amRNSAcquisition: two Clinical Research Units from CRS
29th Jan 20257:00 amRNSTrading update
27th Jan 20257:00 amRNSLOI signed for Phase 3 Whooping Cough trial
21st Jan 20257:00 amRNS£3.2m hLAB project
14th Jan 20257:00 amRNSHolding(s) in Company
13th Jan 20257:00 amRNS-RhMPV challenge model update
10th Dec 20247:00 amRNS£11.5m RSV contract and notice of trading update
19th Nov 20247:00 amRNSHolding(s) in Company
6th Nov 20247:00 amRNSHolding(s) in Company
11th Oct 20247:00 amRNSLong Term Incentive Plan/ PDMR Notification
24th Sep 20247:00 amRNSHolding(s) in Company
17th Sep 20247:00 amRNSHolding(s) in Company
13th Sep 20247:00 amRNSHolding(s) in Company
10th Sep 20247:00 amRNSInterim results
5th Sep 20247:00 amRNSHolding(s) in Company
20th Aug 20247:00 amRNSNotice of results
6th Aug 20243:07 pmRNSHolding(s) in Company
5th Aug 20247:00 amRNSEuronext cancellation
24th Jul 20241:55 pmRNSHolding(s) in Company
23rd Jul 20242:48 pmRNSDirector/PDMR Shareholding
17th Jul 20247:01 amRNSHolding(s) in Company
17th Jul 20247:00 amRNSTrading update
8th Jul 20247:00 amRNSHolding(s) in Company
3rd Jul 20242:48 pmRNSHolding(s) in Company
2nd Jul 20247:02 amRNSChange of registered address
2nd Jul 20247:01 amRNSCapital Markets Day & Notice of trading update
2nd Jul 20247:00 amRNSInfluenza 2b field study contract
3rd Jun 20247:00 amRNS£2.5m contract for Omicron characterisation study
13th May 20241:02 pmRNSResult of AGM
15th Apr 20247:00 amRNSAnnual Report & Notice of AGM
9th Apr 20247:09 amRNSFinal results
27th Mar 20247:00 amRNSNotice of Results
22nd Mar 20243:03 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSHolding(s) in Company
15th Feb 20247:00 amRNSLong Term Incentive Plan / PDMR Notification
14th Feb 20241:14 pmRNSResult of Secondary Placing
14th Feb 20247:00 amRNSProposed Secondary Placing of Ordinary Shares
2nd Feb 202412:44 pmRNSHolding(s) in Company
30th Jan 20247:00 amRNSTrading update
8th Jan 20247:00 amRNSBroker change
2nd Jan 20247:00 amRNS£6.3m HRV contract signed with biotech client
13th Dec 20237:00 amRNS£16.8m RSV contract & Trading ahead of guidance
5th Oct 20237:00 amRNSPositive results from flu human challenge study
12th Sep 20237:00 amRNSInterim results
1st Sep 20237:00 amRNSExercise of Warrants
29th Aug 20237:00 amRNSPlans for a new larger state-of-the-art facility
24th Aug 20237:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.